Symposia: Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical trials, Research, Lymphoid Leukemias, ALL, Adult, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Pediatric, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Real-world evidence, Lymphoid Malignancies, Registries, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Clinical trials, Research, Lymphoid Leukemias, ALL, Adult, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Pediatric, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Real-world evidence, Lymphoid Malignancies, Registries, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 5-6
(Marriott Marquis San Diego Marina)
Moderators:
Selina Luger, MD, FRCPC, University of Pennsylvania
and
Vinod Pullarkat, MD,
Disclosures:
Luger: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Marker Therapeutics: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy. Pullarkat: Abbvie: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria; Amgen: Speakers Bureau; Sobi: Speakers Bureau; Jazz: Speakers Bureau; Alexion: Honoraria; Rigel: Consultancy, Honoraria; sanofi: Consultancy.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH